ArticlePituitary2026
GATA3-positive silent corticotroph adenomas are characterized by large size and massive infrasellar invasion.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeA subgroup of GATA3-positive silent corticotroph adenomas (SCA) was identified by transcriptomics. We aimed to compare clinical, radiological and surgical outcomes of SCA with and without GATA3.
methodsTumor volume calculated using Di Chiro-Nelson formula; microcystic appearance defined as small areas of marked hyperintensity on T2W. Cavernous sinus invasion was assessed with Knosp (grades 3-4 considered invasive), and sellar floor invasion by Hardy-Wilson (grade E as massive invasion). Three to six months after surgery, MRI was repeated to evaluate the extent of the surgical resection, and then annually to assess recurrence or tumor progression, and the need for reoperation or radiotherapy.
resultsAmong 45 SCA, 11 (24.4%) were GATA3-positive. The GATA3 patients were more frequently male (72.7% vs. 29.4%, p = 0.016) and had larger tumor volume [34.8 cm
conclusionAbout one quarter of SCA displayed GATA3-positivity and was seen more frequently in men. GATA3-positive SCA are characterized by large tumor size and massive infrasellar invasion, but not aggressive features as no differences in post-surgical outcomes were detected in our cohort.
Indexed as
Identifiers
42829396What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.